Skip to main content
Gilberto Lopes on Muck Rack

Gilberto Lopes

  • Chief, Division of Medical Oncology, Sylvester Comprehensive Cancer Center
  • Contributor, Oncology News Central
Miami
As seen in: Oncology News Central, BBC, Color Research & Application, Nature, Wiley Online Library, Frontiers in Immunology, MDPI, JAMA Oncology, STAT, The Lancet, Brasil 247 and
Chief MedOnc @SylvesterCancer @UnivMiami. Improving access to cancer meds in LMICs. Editor-in-Chief emeritus JCO GO, Board Member @UICC - chair #ATOMcoalition
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Gilberto

Contact Gilberto, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

El Señor de los Anillos quiere ganar la guerra

|
By Gilberto Lopes
| laondadigital.com.uy
Tiempo de lectura: 11 minutos / Los ingenieros de élite de Silicon Valley tienen la obligación de participar en la defensa de nuestra nación, de nuestros valores. De preservar la ligera ventaja que los Estados Unidos y sus aliados occidentales todavía tienen sobre sus adversarios. Así comienzan Alexander C. Karp, cofundador y CEO de Palantir, y Nicholas W.
Open in Who Shared Issue with article?

Frontline Treatment of Late-Stage EGFR+ Metastatic NSCLC: ​Optimizing an EGFR TKI Backbone or Adopting an Alternative EGFR/MET Bispecific Strategy?

|
By Edgardo S. Santos Castillero, Gilberto Lopes, Estelamari Rodriguez
| Oncology Learning Network Verified
Drs Lopes and Rodriguez debate the evidence supporting optimization of an osimertinib backbone vs an EGFR/MET bispecific approach for frontline treatment of EGFR+ mNSCLC. Drs Lopes and Rodriguez debate the real-world trade-offs of frontline regimens, including time toxicity, quality of life, and cost of care. Drs Lopes and Rodriguez debate how frontline osimertinib- vs amivantamab-based strategies influence subsequent treatment sequencing and long-term management.
Open in Who Shared Issue with article?

Efficacy vs Reality: Do Time Toxicity, Quality of Life, and Cost Tip the Frontline Decision? (Round 2)

|
By Edgardo S. Santos Castillero, Gilberto Lopes, Estelamari Rodriguez
| Oncology Learning Network Verified
Drs Lopes and Rodriguez debate the real-world trade-offs of frontline regimens, including time toxicity, quality of life, and cost of care. To hear arguments related to the pivotal data supporting frontline EGFR+ mNSCLC therapies — osimertinib- vs amivantamab-based regimens, see Round 1. To hear arguments related to the impact of frontline EGFR+ mNSCLC treatment selection on subsequent available therapies — osimertinib- vs amivantamab-based regimens, see Round 3. Dr Santos Castillero: Round two.
Open in Who Shared Issue with article?
See all 69 licensed articles (79 Total)